




# LMA MAD Nasal™

## Needle-free intranasal drug delivery device.



The unique design of LMA MAD Nasal™ enables a seal to be formed with the nostril and atomized particles of medication to be delivered to the nasal mucosa. The particles are then absorbed through the mucosal tissue and into the bloodstream, avoiding first pass metabolism.



Time from presentation to the paediatric ER department to analgesia was significantly reduced with IN vs IV drug delivery ( $p < 0.000$ ).<sup>1</sup>

### IN vs IV drug delivery

Within a few minutes of delivery, serum levels of some medications delivered intranasally are comparable to injectable levels.<sup>2</sup>

### IN vs PR drug delivery

With LMA MAD Nasal™, seizure medication can be administered intranasally:

- ▶ Significantly reduces the likelihood of recurrent seizures in the ED<sup>3</sup>
- ▶ Significantly reduces the need for additional medication to treat ongoing seizures<sup>3</sup>
- ▶ Avoids the embarrassment associated with rectal drug delivery<sup>2</sup>

### IN vs IM & Oral drug delivery

Utilising low molecular weight lipophilic drugs intranasally ensures that molecules are easily absorbed across the nasal mucosa for comparable efficacy vs IM and oral drug delivery.<sup>4,5,6</sup>

**“The intranasal route of administration presents several advantages in small children. It is easily administered to a reluctant child, cannot be spit out and allows a more rapid absorption than when given orally.”**

Talon M. et al., 2009



### Soft conical plug

The plug forms a seal with the nostril preventing expulsion of fluid.

### Malleable stylet

The malleable stylet allows 180° positioning of the nasal plug.

### Accurate dosing

The syringe enables the accurate measurement of drugs to be delivered.

### Atomization spray

The spray atomizes drugs into a fine mist of particles 30-100 microns in size.<sup>4</sup>


### Pressure

High applied pressure ensures that drugs are atomized into a fine mist of particles through the tip of the plug.

### LMA MAD Nasal™: Product specification

PO number	Quantity / case	Quantity / box	Description
MAD100	100	25	Intranasal mucosal atomization device with 3 ml syringe
MAD100OS	100	25	Intranasal mucosal atomization device with 3 ml oral syringe
MAD110	100	25	Intranasal mucosal atomization device with 1 ml syringe
MAD110OS	100	25	Intranasal mucosal atomization device with 1 ml oral syringe
MAD130	100	25	Intranasal mucosal atomization device with 1 ml syringe and vial adaptor
MAD130OS	100	25	Intranasal mucosal atomization device with 1 ml oral syringe and vial adaptor
MAD140	100	25	Intranasal mucosal atomization device with 3 ml syringe and vial adaptor
MAD140OS	100	25	Intranasal mucosal atomization device with 3 ml oral syringe and vial adaptor
MAD300	100	25	Intranasal mucosal atomization device without syringe

Distributed by:



30-0318 Rev. 02/14

TELEFLEX HEADQUARTERS INTERNATIONAL, IRELAND  
Teleflex Medical Europe Ltd., IDA Business and Technology Park,  
Dublin Road, Athlone, Co Westmeath, Ireland  
Phone +353 (0)9 06 46 08 00 Fax +353 (0)14 37 07 73  
orders.intl@teleflex.com



Manufactured by:  
Wolfe Tory Medical, Inc.  
79 West 4500 South  
Salt Lake City, Utah 84107



Consult IFU on this website:  
[www.LMACO.com](http://www.LMACO.com)



Printed on paper from sustainable sources

Teleflex [www.teleflex.com](http://www.teleflex.com) LMA [www.lmaco.com](http://www.lmaco.com)

Copyright © 2014 Teleflex Incorporated. All rights reserved. LMA, LMA MAD, LMA MAD Nasal, MAD, MAD Nasal and LMA Better by Design are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. Wolfe-Tory Medical, Inc. is a wholly owned subsidiary of Teleflex Medical.

XX XX XX – XX XX XX . XXX XXXX . XX/X . XX XX XX

### References:

1. Borland M. et al. Emergency Medicine Australasia 2008; **20**: 515-520.
2. Wolfe T.R., Macfarlane T.C. American Journal of Emergency Medicine 2006; **24**: 343-346.
3. Holsti M. et al. Pediatric Emergency Care 2007; **23** (3): 148-153.
4. Talon M. et al., J Burn Care Research 2009; **30**: 599-605.
5. Pires A. et al. J Pharm Pharmaceut Sci 2009; **12** (3): 288-311.
6. Ahmad S. et al. Lancet 2006; **367**: 1591-1597.



### Clinical evidence



For the latest clinical evidence on LMA MAD Nasal™

[www.lmaco.com/evidence](http://www.lmaco.com/evidence)



For the latest educational videos and clinician testimonials

[www.youtube.com/LaryngealMaskAirway](http://www.youtube.com/LaryngealMaskAirway)



For the latest news from LMA

[www.facebook.com/LMAInternational](http://www.facebook.com/LMAInternational)



Better by Design



For product information and access to product instructions for use

[www.lmaco.com](http://www.lmaco.com)



For information on other products within the Teleflex product portfolio

[www.teleflex.com](http://www.teleflex.com)

